Added Value of Estrogen Receptor, Progesterone Receptor, and L1
Cell Adhesion Molecule Expression to Histology-Based
Endometrial Carcinoma Recurrence Prediction Models: An ENITEC
Collaboration Study

J 2018

Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study

PUTTEN, Louis J. van der; Nicole C. M. VISSER; Ko van de VIJVER; Maria SANTACANA; Peter BRONSERT et al.

Základní údaje

Originální název

Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study

Autoři

Vydání

International Journal of Gynecological Cancer, Philadelphia, Lippincott Williams & Wilkins, 2018, 1048-891X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.746

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/18:00104087

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Endometrial carcinoma; Endometrioid; Nonendometrioid; Estrogen receptor; Progesteron receptor; L1CAM; Prognosis; Immunohistochemistry

Štítky

14110230, 14110411, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 2. 2019 19:59, Soňa Böhmová

Anotace

V originále

Objectives Endometrial carcinoma mortality is mainly caused by recurrent disease, and various immunohistochemical markers to predict recurrences have been studied. Loss of the estrogen receptor (ER) and progesterone receptor (PR) and the presence of the L1 cell adhesion molecule (L1CAM) are promising markers, but their combined value has not been studied. Materials and Methods Expression of ER, PR, and L1CAM was immunohistochemically determined in 293 endometrial carcinomas from 11 collaborating European Network for Individualized Treatment of Endometrial Cancer centers. Estrogen receptor, PR, or L1CAM staining was considered positive or negative when expressed by greater than or equal to 10% or less than 10% of the tumor cells, respectively. The association between these markers and clinicopathological markers, and their combined value in predicting survival were calculated, both in the entire cohort and in a selected groups of stage I endometrioid and low-risk stage I endometrioid carcinomas. Results Estrogen receptor and PR were negative in 19% and 28% of the cases, respectively, and L1CAM was positive in 18%. All 3 were associated with advanced stage, high-grade, nonendometrioid histology, lymphovascular space invasion (LVSI), and reduced disease-free survival. Only advanced stage, loss of PR, and LVSI were associated with reduced disease-free survival in multivariate analysis. A prognostic model including these 3 markers was superior to 1 including only the 3 immunohistochemical markers, which was superior to the traditional model. In both the stage I endometrioid and the low-risk stage I endometrioid groups, only loss of PR was associated with reduced disease-free survival. Conclusions Loss of ER and PR, and the presence of L1CAM are associated with high risk characteristics, and loss of PR is the strongest predictor of recurrent disease. Although a combination of these 3 markers is slightly superior to the traditional histological markers, a prognostic model including stage, PR expression, and LVSI is the most promising model in the identification of high risk carcinomas. In the stage I endometrioid carcinomas, PR immunohistochemistry appears to be of additional value in predicting recurrences.

Citovat

PUTTEN, Louis J. van der; Nicole C. M. VISSER; Ko van de VIJVER; Maria SANTACANA; Peter BRONSERT; Johan BULTEN; Marc HIRSCHFELD; Eva COLAS; Antonio GIL-MORENO; Angel GARCIA; Gemma MANCEBO; Fransesca ALAMEDA; Jone TROVIK; Reidun K. KOPPERUD; Jutta HUVILA; Stefanie SCHRAUWEN; Martin KOSKAS; Francine WALKER; Vít WEINBERGER; Luboš MINÁŘ; Eva JANDÁKOVÁ; Marc P. L. M. SNIJDERS; Sa VAN DEN BERG-VAN ERP; Xavier MATIAS-GUIU; Helga B. SALVESEN; Henrica M. J. WERNER; Frederic AMANT; Leon F. A. G. MASSUGER a Johanna M. A. PIJNENBORG. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. International Journal of Gynecological Cancer. Philadelphia: Lippincott Williams & Wilkins, 2018, roč. 28, č. 3, s. 514-523. ISSN 1048-891X. Dostupné z: https://doi.org/10.1097/IGC.0000000000001187.

@article{1451456,
   author = {Putten, Louis J. van der and Visser, Nicole C. M. and Vijver, Ko van de and Santacana, Maria and Bronsert, Peter and Bulten, Johan and Hirschfeld, Marc and Colas, Eva and GilandMoreno, Antonio and Garcia, Angel and Mancebo, Gemma and Alameda, Fransesca and Trovik, Jone and Kopperud, Reidun K. and Huvila, Jutta and Schrauwen, Stefanie and Koskas, Martin and Walker, Francine and Weinberger, Vít and Minář, Luboš and Jandáková, Eva and Snijders, Marc P. L. M. and van den Bergandvan Erp, Sa and MatiasandGuiu, Xavier and Salvesen, Helga B. and Werner, Henrica M. J. and Amant, Frederic and Massuger, Leon F. A. G. and Pijnenborg, Johanna M. A.},
   article_location = {Philadelphia},
   article_number = {3},
   doi = {https://doi.org/10.1097/IGC.0000000000001187},
   keywords = {Endometrial carcinoma; Endometrioid; Nonendometrioid; Estrogen receptor; Progesteron receptor; L1CAM; Prognosis; Immunohistochemistry},
   language = {eng},
   issn = {1048-891X},
   journal = {International Journal of Gynecological Cancer},
   title = {Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study},
   volume = {28},
   year = {2018}
}

TY  - JOUR
ID  - 1451456
AU  - Putten, Louis J. van der - Visser, Nicole C. M. - Vijver, Ko van de - Santacana, Maria - Bronsert, Peter - Bulten, Johan - Hirschfeld, Marc - Colas, Eva - Gil-Moreno, Antonio - Garcia, Angel - Mancebo, Gemma - Alameda, Fransesca - Trovik, Jone - Kopperud, Reidun K. - Huvila, Jutta - Schrauwen, Stefanie - Koskas, Martin - Walker, Francine - Weinberger, Vít - Minář, Luboš - Jandáková, Eva - Snijders, Marc P. L. M. - van den Berg-van Erp, Sa - Matias-Guiu, Xavier - Salvesen, Helga B. - Werner, Henrica M. J. - Amant, Frederic - Massuger, Leon F. A. G. - Pijnenborg, Johanna M. A.
PY  - 2018
TI  - Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study
JF  - International Journal of Gynecological Cancer
VL  - 28
IS  - 3
SP  - 514-523
EP  - 514-523
PB  - Lippincott Williams & Wilkins
SN  - 1048891X
KW  - Endometrial carcinoma
KW  - Endometrioid
KW  - Nonendometrioid
KW  - Estrogen receptor
KW  - Progesteron receptor
KW  - L1CAM
KW  - Prognosis
KW  - Immunohistochemistry
N2  - Objectives Endometrial carcinoma mortality is mainly caused by recurrent disease, and various immunohistochemical markers to predict recurrences have been studied. Loss of the estrogen receptor (ER) and progesterone receptor (PR) and the presence of the L1 cell adhesion molecule (L1CAM) are promising markers, but their combined value has not been studied. Materials and Methods Expression of ER, PR, and L1CAM was immunohistochemically determined in 293 endometrial carcinomas from 11 collaborating European Network for Individualized Treatment of Endometrial Cancer centers. Estrogen receptor, PR, or L1CAM staining was considered positive or negative when expressed by greater than or equal to 10% or less than 10% of the tumor cells, respectively. The association between these markers and clinicopathological markers, and their combined value in predicting survival were calculated, both in the entire cohort and in a selected groups of stage I endometrioid and low-risk stage I endometrioid carcinomas. Results Estrogen receptor and PR were negative in 19% and 28% of the cases, respectively, and L1CAM was positive in 18%. All 3 were associated with advanced stage, high-grade, nonendometrioid histology, lymphovascular space invasion (LVSI), and reduced disease-free survival. Only advanced stage, loss of PR, and LVSI were associated with reduced disease-free survival in multivariate analysis. A prognostic model including these 3 markers was superior to 1 including only the 3 immunohistochemical markers, which was superior to the traditional model. In both the stage I endometrioid and the low-risk stage I endometrioid groups, only loss of PR was associated with reduced disease-free survival. Conclusions Loss of ER and PR, and the presence of L1CAM are associated with high risk characteristics, and loss of PR is the strongest predictor of recurrent disease. Although a combination of these 3 markers is slightly superior to the traditional histological markers, a prognostic model including stage, PR expression, and LVSI is the most promising model in the identification of high risk carcinomas. In the stage I endometrioid carcinomas, PR immunohistochemistry appears to be of additional value in predicting recurrences.
ER  -

PUTTEN, Louis J. van der; Nicole C. M. VISSER; Ko van de VIJVER; Maria SANTACANA; Peter BRONSERT; Johan BULTEN; Marc HIRSCHFELD; Eva COLAS; Antonio GIL-MORENO; Angel GARCIA; Gemma MANCEBO; Fransesca ALAMEDA; Jone TROVIK; Reidun K. KOPPERUD; Jutta HUVILA; Stefanie SCHRAUWEN; Martin KOSKAS; Francine WALKER; Vít WEINBERGER; Luboš MINÁŘ; Eva JANDÁKOVÁ; Marc P. L. M. SNIJDERS; Sa VAN DEN BERG-VAN ERP; Xavier MATIAS-GUIU; Helga B. SALVESEN; Henrica M. J. WERNER; Frederic AMANT; Leon F. A. G. MASSUGER a Johanna M. A. PIJNENBORG. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. \textit{International Journal of Gynecological Cancer}. Philadelphia: Lippincott Williams \&{} Wilkins, 2018, roč.~28, č.~3, s.~514-523. ISSN~1048-891X. Dostupné z: https://doi.org/10.1097/IGC.0000000000001187.

Přehled o publikaci